Risperidone-induced reversible neutropenia

This case report presents a 44-year-old man with a history of schizophrenia who developed neutropenia on risperidone therapy. The patient’s laboratory reports showed a gradual decline of leukocytes and neutrophils after resolution and rechallenging. This was reversed with the discontinuation of risp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattalai Kailasam, Vasanth, Chima, Victoria, Nnamdi, Uchechukwu, Sharma, Kavita, Shah, Kairav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536090/
https://www.ncbi.nlm.nih.gov/pubmed/28794632
http://dx.doi.org/10.2147/NDT.S141472
_version_ 1783253964958990336
author Kattalai Kailasam, Vasanth
Chima, Victoria
Nnamdi, Uchechukwu
Sharma, Kavita
Shah, Kairav
author_facet Kattalai Kailasam, Vasanth
Chima, Victoria
Nnamdi, Uchechukwu
Sharma, Kavita
Shah, Kairav
author_sort Kattalai Kailasam, Vasanth
collection PubMed
description This case report presents a 44-year-old man with a history of schizophrenia who developed neutropenia on risperidone therapy. The patient’s laboratory reports showed a gradual decline of leukocytes and neutrophils after resolution and rechallenging. This was reversed with the discontinuation of risperidone and by switching to olanzapine. In this case report, we also discuss the updated evidence base for management of risperidone-induced neutropenia.
format Online
Article
Text
id pubmed-5536090
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55360902017-08-09 Risperidone-induced reversible neutropenia Kattalai Kailasam, Vasanth Chima, Victoria Nnamdi, Uchechukwu Sharma, Kavita Shah, Kairav Neuropsychiatr Dis Treat Case Report This case report presents a 44-year-old man with a history of schizophrenia who developed neutropenia on risperidone therapy. The patient’s laboratory reports showed a gradual decline of leukocytes and neutrophils after resolution and rechallenging. This was reversed with the discontinuation of risperidone and by switching to olanzapine. In this case report, we also discuss the updated evidence base for management of risperidone-induced neutropenia. Dove Medical Press 2017-07-25 /pmc/articles/PMC5536090/ /pubmed/28794632 http://dx.doi.org/10.2147/NDT.S141472 Text en © 2017 Kattalai Kailasam et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Kattalai Kailasam, Vasanth
Chima, Victoria
Nnamdi, Uchechukwu
Sharma, Kavita
Shah, Kairav
Risperidone-induced reversible neutropenia
title Risperidone-induced reversible neutropenia
title_full Risperidone-induced reversible neutropenia
title_fullStr Risperidone-induced reversible neutropenia
title_full_unstemmed Risperidone-induced reversible neutropenia
title_short Risperidone-induced reversible neutropenia
title_sort risperidone-induced reversible neutropenia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536090/
https://www.ncbi.nlm.nih.gov/pubmed/28794632
http://dx.doi.org/10.2147/NDT.S141472
work_keys_str_mv AT kattalaikailasamvasanth risperidoneinducedreversibleneutropenia
AT chimavictoria risperidoneinducedreversibleneutropenia
AT nnamdiuchechukwu risperidoneinducedreversibleneutropenia
AT sharmakavita risperidoneinducedreversibleneutropenia
AT shahkairav risperidoneinducedreversibleneutropenia

Ejemplares similares